Patent law

Acceleron Reports Fourth Quarter and Full Year 2020 Financial Results

Thursday, February 25, 2021 - 9:01pm

The Company recognized approximately $23.0 million in royalty revenue from approximately $115 million in net sales of REBLOZYL in the fourth quarter of 2020.

Key Points: 
  • The Company recognized approximately $23.0 million in royalty revenue from approximately $115 million in net sales of REBLOZYL in the fourth quarter of 2020.
  • Costs and Expenses Total costs and expenses for the fourth quarter of 2020 were $83.5 million.
  • Net Loss The Company's net loss for the fourth quarter of 2020 was $57.4 million.
  • The Company will host a webcast and conference call to discuss its fourth quarter and full year 2020 financial results on February 25, 2021, at 5:00 p.m. EST.

Verde Bio Holdings, Inc. Announces Acquisition of Mineral and Royalty Interests

Thursday, February 25, 2021 - 1:30pm

Verde is entitled to the cash flow from production attributable to the acquisition beginning on or after February 1, 2021.

Key Points: 
  • Verde is entitled to the cash flow from production attributable to the acquisition beginning on or after February 1, 2021.
  • Scott Cox, Director and Chief Executive Officer of Verde Bio Holdings, said, "This is an outstanding acquisition and addition to our portfolio of high-quality, revenue producing properties.
  • Verde Bio Holdings, Inc. (OTC: VBHI), is a growing U.S. Energy Company based in Frisco, Texas, engaged in the acquisition of Mineral and Royalty interests in lower risk, onshore oil and gas properties within the major oil and gas plays in the U.S.
  • The Companys dual-focused growth strategy relies primarily on leveraging managements expertise to grow through the strategic acquisition of revenue producing royalty interest and strategic and opportunistic non-operated working interests.

GoldMining's Subsidiary Gold Royalty Increases Size of Proposed IPO

Wednesday, February 24, 2021 - 9:08pm

VANCOUVER, BC, Feb. 24, 2021 /PRNewswire/ -GoldMining Inc. (TSX: GOLD) (NYSE AMERICAN: GLDG) ("GoldMining") announced that its subsidiary, Gold Royalty Corp. ("GRC") has increased the size of its proposed initial public offering (the "IPO") of its units (the "Units") from up to 6,000,000 Units to up to 12,000,0000 Units.

Key Points: 
  • VANCOUVER, BC, Feb. 24, 2021 /PRNewswire/ -GoldMining Inc. (TSX: GOLD) (NYSE AMERICAN: GLDG) ("GoldMining") announced that its subsidiary, Gold Royalty Corp. ("GRC") has increased the size of its proposed initial public offering (the "IPO") of its units (the "Units") from up to 6,000,000 Units to up to 12,000,0000 Units.
  • GRC has applied to list its common shares and the warrants on the NYSE American under the symbols "GROY" and "GROY WS", respectively.
  • GoldMining Inc. is a public mineral exploration company focused on the acquisition and development of gold assets in the Americas.
  • Gold Royalty Corp. is a gold-focused royalty company offering creative financing solutions to the metals and mining industry.

ESPERION Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Company Update

Tuesday, February 23, 2021 - 9:01pm

Even though 2020 was an exceptionally challenging year, we made progress in our mission of Lipid Management for Everyone.

Key Points: 
  • Even though 2020 was an exceptionally challenging year, we made progress in our mission of Lipid Management for Everyone.
  • U.S. product revenue for the fourth quarter and full year ended December 31, 2020 was $8.2 million and $13.0 million, respectively.
  • Royalty revenue for the fourth quarter and full year ended December 31, 2020 was $0.2 million.
  • ESPERION will host a conference call and webcast today, February 23, 2021 at 4:30 P.M. Eastern Time to provide a fourth quarter and full year 2020 financial results and company update.

Xencor Reports Fourth Quarter and Full Year 2020 Financial Results

Tuesday, February 23, 2021 - 9:01pm

In 2020, the Company earned $16.2 million in royalties and, in the fourth quarter of 2020, received a $10 million sales-based milestone payment from Alexion.

Key Points: 
  • In 2020, the Company earned $16.2 million in royalties and, in the fourth quarter of 2020, received a $10 million sales-based milestone payment from Alexion.
  • Revenues for the fourth quarter ended December 31, 2020 were $41.9 million, compared to $3.5 million for the same period in 2019.
  • Research and development expenditures for the fourth quarter ended December 31, 2020 were $47.9 million, compared to $27.3 million for the same period in 2019.
  • ET (1:30 p.m. PT) to discuss these fourth quarter and full year 2020 financial results and provide a corporate update.

Pointivo Lands Eighth Patent Increasing Coverage of the Drone Analytics Market

Tuesday, February 23, 2021 - 6:05pm

Once issued, Pointivo will own eight US patents, with several other US and foreign patent applications pending.

Key Points: 
  • Once issued, Pointivo will own eight US patents, with several other US and foreign patent applications pending.
  • This patent covers the ability to automatically generate engineering CAD drawings from imagery captured from drones and other devices.
  • New Pointivo patent covers ability to automatically generate engineering CAD drawings from imagery captured from drones.
  • Pointivo is a pioneer in the use of AI and computer vision to extract information from imagery derived from various capture methods.

Permianville Royalty Trust Announces Monthly Operational Update

Friday, February 19, 2021 - 9:15pm

Total accrued operating expenses for the period were $1.8 million, a $0.1 million decrease month-over-month from the prior period.

Key Points: 
  • Total accrued operating expenses for the period were $1.8 million, a $0.1 million decrease month-over-month from the prior period.
  • Permianville Royalty Trust is a Delaware statutory trust formed to own a net profits interest representing the right to receive 80% of the net profits from the sale of oil and natural gas production from certain, predominantly non-operated, oil and gas properties in the states of Texas, Louisiana and New Mexico.
  • In addition, future monthly capital expenditures may exceed the average levels experienced in 2019 and prior periods.
  • Neither the Sponsor nor the Trustee intends, and neither assumes any obligation, to update any of the statements included in this press release.

ByteDance Moves to Protect Innovation from the Threat of Patent Litigation by Joining LOT Network

Thursday, February 18, 2021 - 6:00pm

"As champions for the fair use of IP, we encourage other companies to help us make the industry safer by joining LOT Network.

Key Points: 
  • "As champions for the fair use of IP, we encourage other companies to help us make the industry safer by joining LOT Network.
  • ByteDance is sending a strong message that innovation should be protected with patents, and that the global powerhouse and the entire LOT Network community should be protected from patent assertion entities."
  • LOT Network is an international community of the world's leading high-tech companies committed to protecting its members from costly litigation from patent assertion entities (PAEs).
  • LOT Network currently protects more than 1,200 members in 36 countries from litigation from over 3 million worldwide patents and counting.

Athenex Announces U.S. Launch of Klisyri® and Licensing of Additional Territories for Tirbanibulin

Thursday, February 18, 2021 - 12:55pm

Athenex Announces Licensing of Additional Territories for the Development and Commercialization of Tirbanibulin in Japan and South Korea.

Key Points: 
  • Athenex Announces Licensing of Additional Territories for the Development and Commercialization of Tirbanibulin in Japan and South Korea.
  • Athenex announced the licensing of additional territories for tirbanibulin to its partner PharmaEssentia Corp. (Taiwan Exchange: 6446).
  • PharmaEssentia (PEC) adds licensing rights to tirbanibulin for Japan and South Korea to already licensed territories, which include Taiwan, Singapore, and Malaysia.
  • Athenex will also be eligible to receive tiered double-digit royalties on net sales of tirbanibulin in Japan and South Korea.

Provention Bio and Huadong Announce Strategic Collaboration to Develop and Commercialize PRV-3279 in Greater China

Wednesday, February 17, 2021 - 9:00pm

This collaboration provides Provention Bio access to the second largest pharmaceutical market in the world via Huadong's development, regulatory, and commercial capabilities.

Key Points: 
  • This collaboration provides Provention Bio access to the second largest pharmaceutical market in the world via Huadong's development, regulatory, and commercial capabilities.
  • "Provention Bio is a well regarded biopharmaceutical company innovating to intercept and prevent serious autoimmune disorders.
  • Provention Bio is eligible to receive additional milestone payments of up to $172 million if certain regulatory and commercial objectives are achieved.
  • Provention Bio is also eligible to receive low-to-mid double digit royalties as a percentage net sales of PRV-3279 by Huadong in Greater China.